Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation
Forge Biologics, a member of Ajinomoto Bio-Pharma Services and a manufacturer of genetic medicines, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA), the UK’s healthcare regulatory body, granted Innovation Passport designation to the company’s novel AAV gene therapy program, FBX-101, to enter the Innovative Licensing and Access Pathway (ILAP). FBX-101 was created for the treatment of patients with Krabbe disease, a rare neurodegenerative disease that is usually fatal in untreated patients by age two. The ILAP is intended to accelerate regulatory and market access interactions in the UK.
Forge Biologics Announces Positive FBX-101 Clinical Trial Update
Forge Biologics Announces Publication in Human Gene Therapy on a Novel Finding That Changes a Fundamental Understanding of AAV Production
New acquisition to support global gene therapy manufacturing
CDMO Ajinomoto forges ahead with Forge Biologics in $620M acquisition
Forge Biologics, a genetic medicines manufacturing specialist, joined a California-backed organization that aims to boost the development of adeno-associated adenovirus (AAV) gene therapies.
Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs
Forge Biologics to Participate in Multiple September Investor Conferences